首页> 美国政府科技报告 >New Rhenium Radiopharmaceuticals for the Selective Imaging and Therapy of Breast Cancer
【24h】

New Rhenium Radiopharmaceuticals for the Selective Imaging and Therapy of Breast Cancer

机译:新的铼放射性药物用于乳腺癌的选择性成像和治疗

获取原文

摘要

Several novel rhenium-estradiol complexes were synthesized as potential radiopharmaceuticals for the imaging and therapy of breast cancer. Novel palladium catalyzed carbon-carbon and carbon-nitrogen bond-forming chemistry was developed to synthesize phenyl and pyridyl hydrazine derivatives. Polymer-supported hydrazine derivatives were effective labeling substrates for synthesizing organoimidorhenium estradiol complexes. The estradiol-rhenium complexes were fully characterized structurally. The solubility and stability of the organoimidorhenium complexes in aqueous systems was investigated. Pyridylhydrazine derivatives of estradiol were found to form stable rhenium(I) carbonyl complexes, and are excellent candidates for continued investigation as diagnostic and therapeutic radiopharmaceuticals for breast cancer.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号